Clinical Benefits of Low-Dose Vardenafil Treatment

clarithromycinclarithromycin will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

See also:

amiodaroneamiodarone will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors amiodarone will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors apomorphineapomorphine and vardenafil both increase QTc interval. apomorphine and vardenafil both increase QTc interval. aprepitantaprepitant will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Visual disturbances

Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors aprepitant will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors aripiprazolearipiprazole and vardenafil both increase QTc interval. aripiprazole and vardenafil both increase QTc interval. armodafinilarmodafinil will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. armodafinil will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Limit vardenafil dose to 2.5 mg/24 hr clozapineclozapine and vardenafil both increase QTc interval.

clozapine and vardenafil both increase QTc interval. cobicistatcobicistat will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

• Vardenafil 5 mg is not suitable for individuals taking certain heart medications.
• The medication may cause dizziness or lightheadedness in some users.
• Proper storage extends shelf life and maintains potency.
• Lifestyle factors like stress can impact treatment success.
• Avoid heavy meals before taking Vardenafil 5 mg to speed absorption.
• The medication does not work without sexual stimulation.
• Be aware of potential interactions with other prescribed drugs.
• Patients should avoid driving if feeling dizzy after taking it.
• Consult your doctor if you experience prolonged or painful erections.
• Vardenafil 5 mg has a rapid onset but variable duration.
• It is important to review medical history before starting therapy.
• Combination therapy with other ED treatments should only be under medical supervision.

Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors conivaptan will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

• Vardenafil 5 mg is used to treat erectile dysfunction in men.
• It works by increasing blood flow to the penis.
• Vardenafil 5 mg usually starts working within 30-60 minutes.
• The typical dosage for Vardenafil 5 mg is once daily.
• It is available by prescription only.
• Vardenafil 5 mg may cause side effects like headache or flushing.
• It is more effective when taken on an empty stomach.
• Alcohol can increase the risk of side effects with Vardenafil.
• Do not take Vardenafil 5 mg with nitrates or certain medications.
• Store Vardenafil 5 mg in a cool, dry place away from children.
• Consult your doctor before starting Vardenafil 5 mg.
• Report any persistent or severe side effects to your doctor.

Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors cortisonecortisone will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. cortisone will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. crizotinibcrizotinib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

• Vardenafil 5 mg is a PDE5 inhibitor for erectile dysfunction.
• It helps men achieve and maintain an erection suitable for intercourse.
• Vardenafil 5 mg is often prescribed when other treatments fail.
• This medication can be taken with or without food.
• The effects of Vardenafil 5 mg last about 4-6 hours.
• It is important to follow your healthcare provider’s instructions.
• Avoid high-fat meals close to taking Vardenafil for faster effect.
• Combining Vardenafil 5 mg with recreational drugs is dangerous.
• It may interact with blood pressure medications.
• Do not exceed the prescribed dose to prevent risks.
• Vardenafil 5 mg is generally well-tolerated.
• Always check for contraindications before use.

Dose reduction may be needed for coadministered drugs that are pills to increase sex drive male predominantly metabolized by CYP3A. crizotinib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. crofelemercrofelemer increases levels of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Crofelemer has the potential to inhibit CYP3A4 at concentrations expected in the gut; unlikely to inhibit systemically because minimally absorbed. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors. crofelemer increases levels of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. cyclosporinecyclosporine will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors cyclosporine will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

What are the differences between vardenafil and tadalafil?

Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors chloramphenicolchloramphenicol will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors chloramphenicol will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors cimetidinecimetidine will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. cimetidine will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ECG monitoring is recommended, along with drugs that may prolong the QT interval. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors dabrafenibdabrafenib will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. dabrafenib will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. darifenacindarifenacin will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. darifenacin will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Ethical approval

bicalutamidebicalutamide will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors bicalutamide will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors bosentanbosentan will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. bosentan will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. budesonidebudesonide will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Report Problems to the Food and Drug Administration

budesonide will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. butalbitalbutalbital will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. butalbital will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ceritinibceritinib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors ceritinib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. darunavirdarunavir will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Coadministration may increase PDE-5 inhibitor adverse effects including hypotension, syncope, visual changes, and prolonged erection; do not exceed vardenafil 2.5 mg q72hr. darunavir will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Compare 1 Retailer

artemether/lumefantrineartemether/lumefantrine will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. artemether/lumefantrine will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. asenapinevardenafil increases effects of asenapine by pharmacodynamic synergism. vardenafil increases effects of asenapine by pharmacodynamic synergism. atazanaviratazanavir will increase the level or super p force uk effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Mechanism of Action

Limit vardenafil dose to 2.5 mg/24 hr atomoxetineatomoxetine and vardenafil both increase QTc interval. atomoxetine and vardenafil both increase QTc interval. bedaquilinevardenafil and bedaquiline both increase QTc interval. vardenafil and bedaquiline both increase QTc interval. Either increases effects of the other by Mechanism: pharmacodynamic synergism. dasatinibdasatinib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.dasatinib and vardenafil both increase QTc interval.

Pregnancy & Lactation

If unavoidable, obtain ECGs when initiating, during concomitant use, and as clinically indicated. Interrupt ziftomenib with QTc interval > 500 ms or a change from baseline is > 60 ms vardenafil and ziftomenib both increase QTc interval. Interrupt ziftomenib with QTc interval > 500 ms or a change from baseline is > 60 ms zotepinevardenafil increases effects of zotepine by pharmacodynamic synergism. vardenafil increases effects of zotepine by pharmacodynamic synergism. adagrasibadagrasib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Medications & Supplements

Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors adagrasib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors alfuzosinvardenafil and alfuzosin both increase QTc interval. Use Caution/Monitor.alfuzosin and vardenafil both increase QTc interval. vardenafil and alfuzosin both increase QTc interval. Monitor blood pressure response to phosphodiesterase type 5 (PDE5) inhibitors in patients receiving concurrent blood pressure lowering therapy. dasatinib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. deferasiroxdeferasirox will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. deferasirox will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. degarelixdegarelix and vardenafil both increase QTc interval. degarelix and vardenafil both increase QTc interval.

At the maximum recommended dose, deutetrabenazine does not prolong QT interval to a clinically relevant extent.

Certain circumstances may increase risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, coadministration with other drugs that prolong QTc interval, presence of congenital QT prolongation).